ArticleOncology letters2026
Proliferative escalation and possible neuroendocrine carcinoma transformation in pulmonary metastases of a cervical neuroendocrine tumor: A case report.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present report describes a rare case of cervical adenocarcinoma with a coexisting neuroendocrine tumor (NET) G2 component that developed pulmonary metastases with proliferative escalation and possible transformation to neuroendocrine carcinoma (NEC). A 43-year-old woman with cervical adenocarcinoma (International Federation of Gynaecology and Obstetrics 2018 stage IB1) underwent radical hysterectomy, bilateral salpingectomy and pelvic lymph node dissection. The primary tumor had morphologic features of mixed adenocarcinoma and NET G2 [Ki-67, 3-30%; 5-8 mitoses/10 high-power fields (HPFs)], classified as postoperative pathological stage IB1 (pT1b1 N0 M0; American Joint Committee on Cancer 9th edition). After 2 years, chest computed tomography revealed multiple pulmonary nodules. Resection of a right middle lobe lesion revealed metastatic NET with increased proliferative activity (G3 based on gastrointestinal NET criteria; Ki-67 hotspot, 35%; >50 mitoses/10 HPFs). A left upper lobe lesion exhibited predominantly NET morphology, but focal areas exhibited high proliferative activity (Ki-67 hotspot, 93%; 50 mitoses per 10 HPFs) with features compatible with small cell carcinoma. The current case suggests a stepwise progression from NET toward NEC, highlighting the importance of monitoring proliferative indices in cervical NETs, re-evaluating metastatic lesions histologically and considering multimodal treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.